EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials

Khashayar Azimpour iD, Patricia Dorling, Irene Koulinska, Swati Kunduri, Zhiyi Lan, Julia Poritz, Gabriel Tremblay, Angie Raad-Faherty

Advances in Therapy · 2025

DOI: 10.1007/s12325-024-03095-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Therapy, 2025. Verfasst von Khashayar Azimpour und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chiesi, 3800 Steeles Ave. West, Suite 100E, Woodbridge, ON, L4L 4G9, Canada. k.azimpour@chiesi.com. Hauptthemen laut MEDLINE: alpha-Galactosidase, Enzyme Replacement Therapy, Fabry Disease, Quality of Life. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chiesi USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-GalactosidaseEnzyme Replacement TherapyFabry DiseaseQuality of LifeAdultFemaleHumansMaleMiddle AgedCost-Benefit AnalysisHealth StatusQuality-Adjusted Life YearsRecombinant ProteinsClinical Trials, Phase III as TopicMulticenter Studies as TopicRandomized Controlled Trials as TopicIsoenzymes

Stichwörter der Autor:innen

Clinical trialsCost–utility analysesEQ-5D-3LEconomic evaluationFabry diseaseHealth state utility valuesMixed effects modelPegunigalsidase alfaQoLQuality of life

Substanzen

agalsidase alfaalpha-GalactosidaseRecombinant ProteinsIsoenzymes

Autor:innen und Institutionen

  • Chiesi, 3800 Steeles Ave. West, Suite 100E, Woodbridge, ON, L4L 4G9, Canada. k.azimpour@chiesi.com.
  • Chiesi, Boston, MA, USA.
  • Cytel, Inc., Waltham, MA, USA.

ORCID-Profile: Khashayar Azimpour

Förderung

  • Chiesi USA

Zitieren

APA

Azimpour, K., Dorling, P., Koulinska, I., Kunduri, S., Lan, Z., Poritz, J., Tremblay, G., & Raad-Faherty, A. (2025). Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials. Advances in Therapy. https://doi.org/10.1007/s12325-024-03095-2

Vancouver

Azimpour K, Dorling P, Koulinska I, Kunduri S, Lan Z, Poritz J, et al. Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials. Advances in Therapy. 2025. doi:10.1007/s12325-024-03095-2

BibTeX
@article{Azimpour2025,
  author = {Azimpour, Khashayar and Dorling, Patricia and Koulinska, Irene and Kunduri, Swati and Lan, Zhiyi and Poritz, Julia and Tremblay, Gabriel and Raad-Faherty, Angie},
  title = {Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials},
  journal = {Advances in Therapy},
  year = {2025},
  doi = {10.1007/s12325-024-03095-2}
}
Kostenlos starten →